Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program

OBJECTIVE: This analysis of 3,375 adults with overweight/obesity across the Semaglutide Treatment Effect in People with obesity (STEP) 1, 3, and 4 trials evaluated whether more participants with prediabetes had normoglycemia after 68 weeks’ treatment with once-weekly semaglutide 2.4 mg plus lifestyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Perreault, Leigh, Davies, Melanie, Frias, Juan P., Laursen, Peter Nørkjaer, Lingvay, Ildiko, Machineni, Sriram, Varbo, Anette, Wilding, John P.H., Wallenstein, Signe Olrik Rytter, le Roux, Carel W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2022
Materias:
Cardiovascular and Metabolic Risk
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862484/
https://www.ncbi.nlm.nih.gov/pubmed/35724304
http://dx.doi.org/10.2337/dc21-1785

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862484/
https://www.ncbi.nlm.nih.gov/pubmed/35724304
http://dx.doi.org/10.2337/dc21-1785

Ejemplares similares